{
    "nctId": "NCT01433562",
    "briefTitle": "Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients",
    "officialTitle": "Combination of DLBS1425 With Anthracyclin-based Regimen as a Neoadjuvant Therapy in Subjects With Stage II or III Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Clinical response as measured by RECIST",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed stage II or III (operable) primary breast cancer\n* Having radiologically evaluable and measurable lesion(s) of the primary tumor\n* Karnofsky performance status 80 %\n* Normal cardiac function: LVEF \\> 50 %\n* Adequate hematological function: Hb \u2265 10.0 g/dL, WBC \u2265 3,000/mm3, ANC \u2265 1,500 /mm3, platelet count \u2265 100,000/mm3\n* Adequate liver function: ALT \u2264 2.5 times upper limit of normal, total bilirubin level \u2264 1.5 times upper limit of normal\n* Adequate renal function: serum creatinine \u2264 1.5 times upper limit of normal\n* Able to take oral medication\n\nExclusion Criteria:\n\n* Pregnancy or breast feeding subjects\n* History of previous breast cancer (recurrent breast cancer)\n* History of other cancer within the past 5 years\n* Prior systemic treatment for the current breast cancer\n* Prior preoperative topical treatments for the current breast cancer\n* Uncontrolled or serious CVD\n* Known or suspected hypersensitivity to any of the chemotherapeutic agents used in the study\n* Any other serious disease state or medical condition which judged by investigator could interfere with trial participation or trial evaluation\n* Concurrent herbal (alternative) medicines or food supplements suspected to have effect on breast cancer disease within 14 days prior to screening\n* Severe psychological or neurological disorder or dementia that would preclude understanding of the informed consent\n* Participation in any other clinical studies within 30 days prior to screening",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}